JP2018512041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512041A5 JP2018512041A5 JP2017534279A JP2017534279A JP2018512041A5 JP 2018512041 A5 JP2018512041 A5 JP 2018512041A5 JP 2017534279 A JP2017534279 A JP 2017534279A JP 2017534279 A JP2017534279 A JP 2017534279A JP 2018512041 A5 JP2018512041 A5 JP 2018512041A5
- Authority
- JP
- Japan
- Prior art keywords
- deoxy
- nucleotide
- nucleic acid
- antisense strand
- positions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 230000000692 anti-sense effect Effects 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108091081021 Sense strand Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 125000001921 locked nucleotide group Chemical group 0.000 claims 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014266198 | 2014-12-26 | ||
| JP2014266198 | 2014-12-26 | ||
| US201562184209P | 2015-06-24 | 2015-06-24 | |
| US62/184,209 | 2015-06-24 | ||
| US201562266668P | 2015-12-13 | 2015-12-13 | |
| US62/266,668 | 2015-12-13 | ||
| PCT/US2015/067557 WO2016106402A1 (en) | 2014-12-26 | 2015-12-28 | Rna interference agents for p21 gene modulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512041A JP2018512041A (ja) | 2018-05-10 |
| JP2018512041A5 true JP2018512041A5 (https=) | 2019-02-14 |
| JP6865169B2 JP6865169B2 (ja) | 2021-04-28 |
Family
ID=56151549
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534279A Active JP6865169B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ干渉剤 |
| JP2017534287A Pending JP2018513669A (ja) | 2014-12-26 | 2015-12-28 | Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤 |
| JP2017534275A Pending JP2018512373A (ja) | 2014-12-26 | 2015-12-28 | Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 |
| JP2017534294A Active JP6730285B2 (ja) | 2014-12-26 | 2015-12-28 | Ｒｎａ干渉組成物及び悪性腫瘍のための方法 |
| JP2017534286A Active JP6793649B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ剤 |
| JP2017534274A Pending JP2018513104A (ja) | 2014-12-26 | 2015-12-28 | Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法 |
| JP2017534297A Active JP6457645B2 (ja) | 2014-12-26 | 2015-12-28 | ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2021183788A Active JP7307137B2 (ja) | 2014-12-26 | 2021-11-11 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2023106970A Active JP7655971B2 (ja) | 2014-12-26 | 2023-06-29 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2025046972A Pending JP2025102833A (ja) | 2014-12-26 | 2025-03-21 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534287A Pending JP2018513669A (ja) | 2014-12-26 | 2015-12-28 | Ｇｓｔ−ｐｉ遺伝子調節のためのｒｎａ剤 |
| JP2017534275A Pending JP2018512373A (ja) | 2014-12-26 | 2015-12-28 | Ｋｒａｓ突然変異に関連する悪性腫瘍に対する治療のための方法及び組成物 |
| JP2017534294A Active JP6730285B2 (ja) | 2014-12-26 | 2015-12-28 | Ｒｎａ干渉組成物及び悪性腫瘍のための方法 |
| JP2017534286A Active JP6793649B2 (ja) | 2014-12-26 | 2015-12-28 | Ｐ２１遺伝子調節のためのｒｎａ剤 |
| JP2017534274A Pending JP2018513104A (ja) | 2014-12-26 | 2015-12-28 | Ｈｓｐ４７及びｐ２１を標的とするｒｎａｉ分子による悪性腫瘍の治療用組成物及び方法 |
| JP2017534297A Active JP6457645B2 (ja) | 2014-12-26 | 2015-12-28 | ＧＳＴ−π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2021183788A Active JP7307137B2 (ja) | 2014-12-26 | 2021-11-11 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2023106970A Active JP7655971B2 (ja) | 2014-12-26 | 2023-06-29 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
| JP2025046972A Pending JP2025102833A (ja) | 2014-12-26 | 2025-03-21 | ＧＳＴ－π遺伝子を調節するためのＲＮＡ干渉剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (14) | US10264976B2 (https=) |
| EP (9) | EP3236973A4 (https=) |
| JP (10) | JP6865169B2 (https=) |
| KR (4) | KR20170096199A (https=) |
| CN (7) | CN107106564A (https=) |
| AU (4) | AU2015369596A1 (https=) |
| BR (2) | BR112017013599A2 (https=) |
| CA (4) | CA2972270A1 (https=) |
| RU (4) | RU2017126601A (https=) |
| WO (7) | WO2016106404A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180002702A1 (en) * | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US10792299B2 (en) | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US10264976B2 (en) * | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US11045488B2 (en) | 2014-12-26 | 2021-06-29 | Nitto Denko Corporation | RNA interference agents for GST-π gene modulation |
| ES2789049T3 (es) * | 2014-12-26 | 2020-10-23 | Nitto Denko Corp | Agentes de interferencia de ARN para modulación génica de GST-pi |
| EP3313449B1 (en) * | 2015-06-24 | 2020-09-23 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
| JP6457704B2 (ja) * | 2015-12-13 | 2019-01-23 | 日東電工株式会社 | 高活性及びオフターゲット削減のためのｓｉＲＮＡ構造 |
| TWI780046B (zh) | 2016-05-10 | 2022-10-11 | 國立大學法人東京醫科齒科大學 | 炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法 |
| JP2019508379A (ja) * | 2017-02-16 | 2019-03-28 | 日東電工株式会社 | 悪性腫瘍に対する治療方法及び治療用組成物 |
| AU2018359904B2 (en) * | 2017-11-06 | 2023-02-23 | Nitto Denko Corporation | Fusogenic compounds for delivery of biologically active molecules |
| SG11202004097RA (en) * | 2017-11-09 | 2020-06-29 | Univ Nat Corp Tokyo Medical & Dental | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method |
| CN109777798A (zh) * | 2017-11-13 | 2019-05-21 | 深圳华大生命科学研究院 | 一种基于CRISPR技术治疗KRAS突变恶性肿瘤的sgRNA及其应用 |
| JP6952594B2 (ja) * | 2017-12-15 | 2021-10-20 | 洋司郎 新津 | 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物 |
| CN108486011B (zh) * | 2018-03-27 | 2020-05-05 | 山东大学 | 一种三联苯化合物、制备方法及其应用 |
| JP7432929B2 (ja) * | 2018-05-31 | 2024-02-19 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | マイクロｒｎａの非正規標的を抑制するｒｎａ干渉誘導核酸およびその用途 |
| WO2020009189A1 (ja) * | 2018-07-05 | 2020-01-09 | 洋司郎 新津 | Ｂｒａｆ阻害剤によるがん細胞の逆説的増殖を抑制する薬剤 |
| WO2020040186A1 (ja) | 2018-08-22 | 2020-02-27 | 日東電工株式会社 | Ｈｓｐ４７の阻害物質を用いた、がん転移抑制 |
| JP7453145B2 (ja) * | 2018-08-22 | 2024-03-19 | 日東電工株式会社 | Ｈｓｐ４７の阻害物質を用いた、化学療法剤感受性の増強 |
| EP4365289A3 (en) * | 2018-11-16 | 2024-07-10 | Nitto Denko Corporation | Rna interference delivery formulation and methods for malignant tumors |
| CN113038956A (zh) * | 2018-12-05 | 2021-06-25 | 日东电工株式会社 | 癌处置用RNAi分子 |
| WO2020145350A1 (ja) | 2019-01-10 | 2020-07-16 | 国立大学法人大阪大学 | 免疫賦活用組成物 |
| WO2020196736A1 (ja) * | 2019-03-28 | 2020-10-01 | 日東電工株式会社 | ＲＮＡｉ分子 |
| JP2019116507A (ja) * | 2019-04-25 | 2019-07-18 | 有限会社オービット | Ｈｓｐ４７の発現促進剤、脱毛抑制方法、Ｈｓｐ４７の発現促進剤の製造方法及び飲食物の製造方法 |
| US20230027604A1 (en) * | 2019-07-02 | 2023-01-26 | Argonaute RNA Limited | Apolipoprotein b antagonist |
| WO2021020412A1 (ja) * | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
| EP4090744A4 (en) * | 2020-01-17 | 2024-04-10 | Anastasia Khvorova | UNIVERSAL DYNAMIC PHARMACOKINETIC MODIFYING ANCHORS |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| CN112280800B (zh) * | 2020-10-19 | 2022-06-07 | 上海市东方医院（同济大学附属东方医院） | 一种构建体及其在制备动物衰老细胞示踪和衰老细胞清除药物中的应用 |
| WO2022144883A2 (en) | 2020-12-28 | 2022-07-07 | 1E Therapeutics, Ltd. | P21 mrna targeting dnazymes |
| EP4267741A2 (en) | 2020-12-28 | 2023-11-01 | 1E Therapeutics, Ltd. | P21 mrna target areas for silencing |
| KR102732910B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732909B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732911B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732912B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| KR102732913B1 (ko) * | 2021-12-29 | 2024-11-20 | 의료법인 명지의료재단 | K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 |
| US20250290076A1 (en) * | 2022-04-27 | 2025-09-18 | Kyoto University | Epicardial cell regeneration promoter and method for promoting epicardial cell regeneration |
| TW202529777A (zh) * | 2023-09-28 | 2025-08-01 | 日商日東電工股份有限公司 | 組合療法 |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970005898B1 (ko) | 1987-09-21 | 1997-04-21 | 젠- 프로우브 인코퍼레이티드 | 뉴클레오티드 프로브에 대한 비-뉴클레오티드 연결시약 |
| US5204241A (en) | 1990-10-22 | 1993-04-20 | Oxi-Gene Inc. | Glutathione-S-transferase mu as a measure of drug resistance |
| US5786336A (en) | 1991-04-29 | 1998-07-28 | Terrapin Technologies, Inc. | Target-selective protocols based on mimics |
| US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
| WO1995006731A2 (en) | 1993-09-02 | 1995-03-09 | Ribozyme Pharmaceuticals, Inc. | Non-nucleotide containing enzymatic nucleic acid |
| EP0725788B1 (en) | 1993-10-27 | 1998-12-16 | Ribozyme Pharmaceuticals, Inc. | 2'-amido and 2'-peptido modified oligonucleotides |
| JPH11507056A (ja) | 1995-06-07 | 1999-06-22 | テラピン テクノロジーズ、インク． | グルタチオンアナログの代謝的効果 |
| US5968737A (en) | 1996-11-12 | 1999-10-19 | The University Of Mississippi | Method of identifying inhibitors of glutathione S-transferase (GST) gene expression |
| JPH10330249A (ja) * | 1997-05-30 | 1998-12-15 | Kureha Chem Ind Co Ltd | レチノール化合物含有ｈｓｐ４７合成抑制剤 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| TW576838B (en) | 1998-04-16 | 2004-02-21 | Teijin Ltd | Glutathione derivatives and application form thereof |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| WO2005019453A2 (en) * | 2001-05-18 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20070083945A1 (en) * | 2000-03-10 | 2007-04-12 | Byrum Joseph R | Nucleic acid molecules and other molecules associated with plants |
| US20030144236A1 (en) | 2000-03-29 | 2003-07-31 | Weiss Robert H | Novel specific inhibitor of the cyclin kinase inhibitor p21 (wafl/cip1) |
| AU2002210791A1 (en) * | 2000-07-28 | 2002-02-13 | Compugen Inc. | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
| US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20030099974A1 (en) | 2001-07-18 | 2003-05-29 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| JP3803318B2 (ja) * | 2001-11-21 | 2006-08-02 | 株式会社ＲＮＡｉ | 遺伝子発現阻害方法 |
| US20040029275A1 (en) * | 2002-08-10 | 2004-02-12 | David Brown | Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs |
| EP2305812A3 (en) | 2002-11-14 | 2012-06-06 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| WO2004055165A2 (en) | 2002-12-13 | 2004-07-01 | St. Jude Children's Research Hospital | Glutathione-s-transferase test for susceptibility to parkinson's |
| WO2004094636A1 (en) | 2003-04-24 | 2004-11-04 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| US20050142596A1 (en) | 2003-11-14 | 2005-06-30 | Krolewski Andrzej S. | Methods of diagnosing renal and cardiovascular disease |
| AU2005222965B8 (en) | 2004-03-15 | 2010-07-01 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| CA2566519C (en) | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| EP2386640B1 (en) | 2004-08-26 | 2015-01-28 | EnGeneIC Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells |
| ES2900801T3 (es) | 2004-12-22 | 2022-03-18 | Nitto Denko Corp | Portador de fármacos y kit de portador de fármacos para inhibir la fibrosis |
| US9393315B2 (en) * | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| WO2006113679A2 (en) | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Delivery of sirna by neutral lipid compositions |
| US20070134687A1 (en) * | 2005-09-12 | 2007-06-14 | Aurelium Biopharma Inc. | Focused microarray and methods of diagnosing cancer |
| ES2324128A1 (es) * | 2005-09-29 | 2009-07-30 | Proyecto De Biomedicina Cima, S.L. | Metodo para el diagnostico de carcinoma hepatocelular mediante el empleo de marcadores moleculares. |
| WO2007049955A1 (en) | 2005-10-25 | 2007-05-03 | Het Nederlands Kanker Instituut | Prediction of local recurrence of breast cancer |
| RU2448974C2 (ru) * | 2005-11-01 | 2012-04-27 | Элнилэм Фармасьютикалз, Инк. | РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА |
| EP2202239A1 (en) | 2005-11-01 | 2010-06-30 | Alnylam Pharmaceuticals Inc. | RNAI inhibition of influenza virus replication |
| US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| EP1948213B1 (en) | 2005-11-17 | 2009-02-04 | The Children's Medical Center Corporation | Methods to predict and prevent resistance to taxoid compounds |
| US7729737B2 (en) | 2005-11-22 | 2010-06-01 | Isense Corporation | Method and apparatus for background current arrangements for a biosensor |
| CA2631677C (en) | 2005-12-01 | 2014-08-12 | Pronai Therapeutics, Inc. | Amphoteric liposome formulation |
| US9572886B2 (en) * | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| JP5342834B2 (ja) * | 2008-09-05 | 2013-11-13 | 日東電工株式会社 | 骨髄線維症処置剤 |
| WO2007130604A2 (en) * | 2006-05-04 | 2007-11-15 | Baylor Research Institute | Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna |
| ES2874149T3 (es) | 2006-05-11 | 2021-11-04 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión del gen PCSK9 |
| US8067390B2 (en) | 2007-03-02 | 2011-11-29 | The Board Of Regents Of The University Of Texas System | Therapeutic targeting of interleukins using siRNA in neutral liposomes |
| TWI407971B (zh) | 2007-03-30 | 2013-09-11 | 日東電工股份有限公司 | Cancer cells and tumor-related fibroblasts |
| WO2008124634A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
| ES2428009T3 (es) | 2007-07-05 | 2013-11-05 | Novartis Ag | ARNds para tratar infecciones virales |
| JP2010537640A (ja) * | 2007-08-27 | 2010-12-09 | ボストン バイオメディカル， インコーポレイテッド | マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物 |
| WO2009033284A1 (en) * | 2007-09-14 | 2009-03-19 | Mcmaster University | Inhibitors of collagen biosynthesis as anti-tumor agents |
| CA2715796C (en) * | 2008-03-06 | 2015-04-28 | Rottapharm S.P.A. | 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| US20110223665A1 (en) | 2008-07-25 | 2011-09-15 | Alnylam Pharmaceuticals, Inc. | ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND |
| AU2008359989A1 (en) * | 2008-07-30 | 2010-02-04 | Nitto Denko Corporation | Drug carriers |
| CA2816925C (en) * | 2009-11-04 | 2023-01-10 | The University Of British Columbia | Nucleic acid-containing lipid particles and related methods |
| KR101718534B1 (ko) * | 2009-12-09 | 2017-03-22 | 닛토덴코 가부시키가이샤 | Ｈｓｐ４７ 발현의 조절 |
| CN106995844A (zh) | 2010-02-24 | 2017-08-01 | 波蒂塞克股份有限公司 | 确定基因‑营养物的相互作用的方法 |
| WO2011112954A1 (en) | 2010-03-12 | 2011-09-15 | The Wistar Institute | Inhibition of p21 and use thereof for inducing tissue regeneration |
| US8372819B2 (en) * | 2010-04-11 | 2013-02-12 | Salk Institute For Biological Studies | Methods and compositions for targeting skip |
| WO2011131472A1 (en) * | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| AU2011249406B2 (en) | 2010-05-06 | 2015-05-14 | Stem Cell Medicine Ltd. | Stem cell bank for personalized medicine |
| JP5950428B2 (ja) * | 2010-08-05 | 2016-07-13 | 日東電工株式会社 | 線維化組織から正常組織を再生するための組成物 |
| CN103221055A (zh) | 2010-09-30 | 2013-07-24 | 日东电工株式会社 | Timp1和timp2表达的调节 |
| US9339513B2 (en) | 2010-11-09 | 2016-05-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
| CN107043334B (zh) | 2011-06-08 | 2020-06-16 | 日东电工株式会社 | 用于定向药物输送和增强siRNA活性的化合物 |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| US9011903B2 (en) * | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
| RU2639459C2 (ru) * | 2011-06-21 | 2017-12-21 | Нитто Денко Корпорейшн | Апоптоз-индуцирующее средство |
| CN102896619B (zh) * | 2011-07-26 | 2015-04-22 | 苏州宝时得电动工具有限公司 | 动力工具及其操作方法 |
| US20140351961A1 (en) * | 2011-08-31 | 2014-11-27 | Alexzander A. Asea | Compositions and methods for treatment of metastatic cancer |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| EP2780455B1 (en) * | 2011-11-17 | 2017-07-05 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np) |
| US20150080320A1 (en) * | 2012-05-16 | 2015-03-19 | Aadigen, Llc | Multi-target modulation for treating fibrosis and inflammatory conditions |
| US20140134158A1 (en) | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| SI2858974T1 (sl) * | 2012-06-08 | 2019-01-31 | Nitto Denko Corporation | Lipidi za formulacije za dostavo terapevtskega sredstva |
| US9907828B2 (en) | 2012-06-22 | 2018-03-06 | The University Of Vermont And State Agricultural College | Treatments of oxidative stress conditions |
| WO2014006020A1 (en) * | 2012-07-02 | 2014-01-09 | Fibrostatin, S.L. | Gpbp-1 inhibition and its therapeutic use |
| WO2014022739A2 (en) | 2012-08-03 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
| JP6340162B2 (ja) | 2012-12-20 | 2018-06-06 | 日東電工株式会社 | アポトーシス誘導剤 |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| CN103695421B (zh) | 2013-12-09 | 2016-06-15 | 浙江大学 | 一种特异抑制p21基因表达的siRNA及其应用 |
| US20160187319A1 (en) | 2014-12-26 | 2016-06-30 | Nitto Denko Corporation | Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth |
| WO2016104588A1 (ja) * | 2014-12-26 | 2016-06-30 | 日東電工株式会社 | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| US10792299B2 (en) * | 2014-12-26 | 2020-10-06 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| US20180002702A1 (en) | 2014-12-26 | 2018-01-04 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
| JP6457704B2 (ja) * | 2015-12-13 | 2019-01-23 | 日東電工株式会社 | 高活性及びオフターゲット削減のためのｓｉＲＮＡ構造 |
| JP6899201B2 (ja) | 2016-06-23 | 2021-07-07 | 日東電工株式会社 | 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物 |
-
2015
- 2015-11-06 US US14/934,665 patent/US10264976B2/en not_active Expired - Fee Related
- 2015-12-28 EP EP15874367.4A patent/EP3236973A4/en not_active Withdrawn
- 2015-12-28 US US14/979,571 patent/US9695206B2/en active Active
- 2015-12-28 US US14/979,573 patent/US9580710B2/en not_active Ceased
- 2015-12-28 US US14/979,567 patent/US10047110B2/en active Active
- 2015-12-28 WO PCT/US2015/067559 patent/WO2016106404A2/en not_active Ceased
- 2015-12-28 KR KR1020177020900A patent/KR20170096199A/ko not_active Withdrawn
- 2015-12-28 WO PCT/US2015/067560 patent/WO2016106405A1/en not_active Ceased
- 2015-12-28 JP JP2017534279A patent/JP6865169B2/ja active Active
- 2015-12-28 KR KR1020177020898A patent/KR102527430B1/ko active Active
- 2015-12-28 CA CA2972270A patent/CA2972270A1/en not_active Abandoned
- 2015-12-28 CA CA2971881A patent/CA2971881C/en active Active
- 2015-12-28 CN CN201580071232.9A patent/CN107106564A/zh active Pending
- 2015-12-28 CA CA2972268A patent/CA2972268A1/en not_active Abandoned
- 2015-12-28 AU AU2015369596A patent/AU2015369596A1/en not_active Abandoned
- 2015-12-28 WO PCT/US2015/067561 patent/WO2016106406A2/en not_active Ceased
- 2015-12-28 RU RU2017126601A patent/RU2017126601A/ru unknown
- 2015-12-28 AU AU2015369598A patent/AU2015369598A1/en not_active Abandoned
- 2015-12-28 CN CN201580071233.3A patent/CN107108686B/zh active Active
- 2015-12-28 EP EP15874365.8A patent/EP3236969A4/en not_active Withdrawn
- 2015-12-28 US US14/979,577 patent/US20160215286A1/en not_active Abandoned
- 2015-12-28 JP JP2017534287A patent/JP2018513669A/ja active Pending
- 2015-12-28 CN CN201580071210.2A patent/CN108064153A/zh active Pending
- 2015-12-28 RU RU2017126598A patent/RU2017126598A/ru not_active Application Discontinuation
- 2015-12-28 CA CA2972265A patent/CA2972265A1/en not_active Abandoned
- 2015-12-28 AU AU2015369595A patent/AU2015369595A1/en not_active Abandoned
- 2015-12-28 EP EP15874362.5A patent/EP3236975A4/en not_active Ceased
- 2015-12-28 CN CN201580071191.3A patent/CN107106591B/zh active Active
- 2015-12-28 BR BR112017013599-0A patent/BR112017013599A2/pt not_active Application Discontinuation
- 2015-12-28 JP JP2017534275A patent/JP2018512373A/ja active Pending
- 2015-12-28 CN CN201580071081.7A patent/CN108064155B/zh active Active
- 2015-12-28 WO PCT/US2015/067556 patent/WO2016106401A2/en not_active Ceased
- 2015-12-28 US US14/979,568 patent/US10405749B2/en active Active
- 2015-12-28 BR BR112017013597-3A patent/BR112017013597B1/pt active IP Right Grant
- 2015-12-28 US US14/979,566 patent/US9771582B2/en not_active Ceased
- 2015-12-28 KR KR1020177020901A patent/KR20170093988A/ko not_active Withdrawn
- 2015-12-28 WO PCT/US2015/067558 patent/WO2016106403A2/en not_active Ceased
- 2015-12-28 EP EP20207751.7A patent/EP3798308A1/en active Pending
- 2015-12-28 JP JP2017534294A patent/JP6730285B2/ja active Active
- 2015-12-28 WO PCT/US2015/067557 patent/WO2016106402A1/en not_active Ceased
- 2015-12-28 RU RU2017126613A patent/RU2719185C2/ru active
- 2015-12-28 JP JP2017534286A patent/JP6793649B2/ja active Active
- 2015-12-28 AU AU2015369592A patent/AU2015369592B2/en active Active
- 2015-12-28 EP EP20156350.9A patent/EP3683309A1/en active Pending
- 2015-12-28 US US14/979,574 patent/US10047111B2/en not_active Ceased
- 2015-12-28 EP EP15874364.1A patent/EP3236945B1/en active Active
- 2015-12-28 KR KR1020177020894A patent/KR20170098929A/ko not_active Withdrawn
- 2015-12-28 WO PCT/US2015/067553 patent/WO2016106400A2/en not_active Ceased
- 2015-12-28 EP EP15874363.3A patent/EP3236976B1/en active Active
- 2015-12-28 EP EP15874361.7A patent/EP3236974B9/en active Active
- 2015-12-28 CN CN201580071209.XA patent/CN107106592B/zh active Active
- 2015-12-28 JP JP2017534274A patent/JP2018513104A/ja active Pending
- 2015-12-28 JP JP2017534297A patent/JP6457645B2/ja active Active
- 2015-12-28 CN CN201580071234.8A patent/CN108024961A/zh active Pending
- 2015-12-28 RU RU2017126610A patent/RU2756253C2/ru active
- 2015-12-28 EP EP15874366.6A patent/EP3240796B1/en active Active
-
2017
- 2017-04-17 US US15/489,650 patent/US20170218365A1/en not_active Abandoned
- 2017-06-27 US US15/634,771 patent/US10023597B2/en active Active
-
2019
- 2019-09-19 US US16/576,102 patent/USRE48887E1/en active Active
-
2020
- 2020-02-28 US US16/804,696 patent/USRE49229E1/en active Active
- 2020-08-11 US US16/990,860 patent/USRE49431E1/en active Active
-
2021
- 2021-11-11 JP JP2021183788A patent/JP7307137B2/ja active Active
- 2021-11-12 US US17/454,757 patent/US20220087531A1/en not_active Abandoned
-
2023
- 2023-06-29 JP JP2023106970A patent/JP7655971B2/ja active Active
-
2025
- 2025-03-21 JP JP2025046972A patent/JP2025102833A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512041A5 (https=) | ||
| JP2018512110A5 (https=) | ||
| EP4455285A3 (en) | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof | |
| Morris | siRNA-mediated transcriptional gene silencing: the potential mechanism and a possible role in the histone code | |
| JP2018512060A5 (https=) | ||
| JP2018513668A5 (https=) | ||
| EP4527459A3 (en) | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | |
| JP2016116520A5 (https=) | ||
| JP2018507711A5 (https=) | ||
| RU2017132895A (ru) | Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента | |
| JP2014527401A5 (https=) | ||
| Pasternak et al. | Unlocked nucleic acid–an RNA modification with broad potential | |
| JP2013226147A5 (https=) | ||
| JP2017537626A5 (https=) | ||
| JP2017079776A5 (https=) | ||
| JP2013511990A5 (https=) | ||
| EA201690274A1 (ru) | Способ сайт-специфического ферментативного мечения нуклеиновых кислот in vitro введением не встречающихся в природе нуклеотидов | |
| JP2013535212A5 (https=) | ||
| JP2016522674A5 (https=) | ||
| JP2015519057A5 (https=) | ||
| JP2015523853A5 (https=) | ||
| JP2018519835A5 (https=) | ||
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| JP2016520310A5 (https=) | ||
| JP2015511821A5 (https=) |